Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19203182 | 0.85 | BTK (0.50) | ACACBBTKNAMPT | |
| SCHEMBL19202629 | 0.81 | BTK (0.54) | ACACBPKMBTKGPR119 | |
| SCHEMBL22619202 | 0.74 | PIK3CD (0.43) | ACACBCDK7CDK13CDK12NAMPT | |
| SCHEMBL31479266 | 0.73 | NR1H2 (0.40) | ACACBNAMPTNR1H2 | |
| SCHEMBL19202628 | 0.73 | BTK (0.55) | ACACBBTKGPR119 | |
| SCHEMBL19877675 | 0.72 | PKM (0.42) | PKMNAMPTATRBACE1 | |
| SCHEMBL3466461 | 0.71 | PDK4 (0.44) | NAMPTGPR119NR1H2 | |
| SCHEMBL19202630 | 0.71 | MAP2K4 (0.50) | ACACBPKMACACA | |
| SCHEMBL2951348 | 0.71 | NAMPT (0.60) | PKMCDK7CDK13CDK12NAMPT | |
| SCHEMBL31598654 | 0.71 | NR1H2 (0.42) | NAMPTGPR119NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3409672-B1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2021-12-08 | — | — | EP | disclosed |
| US-10336755-B2 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-07-02 | — | — | US | disclosed |
| US-20190016721-A1 | FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| WO-2017128917-A1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | 北京诺诚健华医药科技有限公司 | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336755-B2 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases | BTK, SYK, JAK1 | ACACB 3969/4885PKM 663/4885ACACA 4138/4885 |
| US-20190016721-A1 | FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BTK, SYK, JAK1 | ACACB 3969/4885PKM 663/4885ACACA 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.